Name | IRAK4-IN-17 |
---|
Description | IRAK4-IN-17 (Compound 5) is a potent IRAK4 inhibitor with the IC50 of 1.3 nM[1]. IRAK4-IN-17 can be used in large B-cell lymphoma (DLBCL) research[1]. |
---|---|
Related Catalog | |
Target |
IRAK4:1.3 nM (IC50) |
In Vitro | IRAK4-IN-17 (0.7-40.1 μM; 72 h) selectively suppresses OCI-LY10 and TMD8 cells with MYD88 L265P mutation[1]. IRAK4-IN-17 (0.3-10 μM; 2 h) inhibits the viability of DLBCL cells by targeting IRAK4 signaling[1]. Cell Cytotoxicity Assay[1] Cell Line: OCI-LY10, TMD8, Ramos and HT cells Concentration: 0.7-40.1 μM Incubation Time: 72 hours Result: Suppressed OCI-LY10 and TMD8 cells with MYD88 L265P mutation (IC50=0.7 μM and 1.2 μM, respectively), but not Ramos and HT cell lines with WT MYD88 (IC50=11.4 μM and 40.1 μM, respectively). Western Blot Analysis[1] Cell Line: OCI-LY10 and TMD8 cells Concentration: 0.3, 1, 3 and 10 μM Incubation Time: 2 hours Result: Inhibited the phosphorylation of IRAK4 and the downstream molecules, IKKβ and NF-κB transcription factor (p65) in OCI-LY10 and TMD8 cells. |
References |
Molecular Formula | C17H20F2N8O |
---|---|
Molecular Weight | 390.39 |